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Abstract
Objective: To determine the significance of an extended 10-core transrectal biopsy protocol in different categories of 
patients with suspected prostate cancer using digital guidance.
Materials and Methods: We studied 125 men who were being evaluated for prostate cancer. They all had an extended 
10-core digitally guided transrectal prostatic biopsy done for either an elevated serum prostate-specific antigen (PSA) or 
an abnormal digital rectal examination finding or both. Sextant biopsy samples were collected first, followed by additional 
four lateral biopsies in all patients. Both groups of specimens were analyzed separately. The cancer detection rates 
of both sextant and extended 10-core biopsy protocols at different PSA levels and digital rectal examination (DRE) 
findings were determined and compared. The level of significance of difference in cancer detection was determined 
using Pearson’s Chi square test with level of significance set at <0.05.
Results: The overall cancer detection by the extended technique was 61 (48.8%) cases while the sextant protocol 
detected cancer in 52 cases. The 10-core extended protocol yielded an increase in cancer detection rate of 14.8% but 
the improvement in detection rate was only statistically significant in the sub-set of patients with PSA between 4.1 and 
10 ng/mL, with or without abnormality on DRE, with an overall increase detection rate of 33%.(P=0.04)
Conclusion: Our study has shown that a 10-core prostate biopsy protocol significantly improves cancer detection in 
patients with suspected early cancer. It should therefore be the optimum biopsy protocol for patients with gray-zone 
PSA value, with or without abnormal DRE.
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Introduction
Carcinoma of the prostate is the second leading cause 
of death due to neoplastic diseases and accounts for 
approximately 10% of all malignant neoplasms in men 
worldwide.[1] This disease is an age-related pathology and as 
such destined to be increasingly relevant in an aging general 
population.[2] The preemptive measures and strategies being 
developed are aimed at diagnosing tumors at an earlier stage 
with the aim of improving survival. The major tools for early 
diagnosis include the prostate-specific antigen (PSA) level, 
digital rectal examination (DRE), and imaging studies.[3]
With the emphasis on early detection of prostate cancer, 
the importance of prostate biopsy methods have been 
recognized. A sextant (six-core) biopsy is generally regarded 
as adequate to make the diagnosis as demonstrated by Hodge 
et al.,[4] and it is still being practiced by most urologists. 
However, some researchers have demonstrated an increase 
in cancer detection if an extended biopsy protocol, which 
incorporates biopsy of the peripheral zone into the traditional 
para-sagittal sextant biopsies, is employed (ranging from 
eight to 26 cores).[5-8] Systematic biopsy of the peripheral 
zone (PZ), which can be obtained by laterally directing the 
biopsy needle in the prostate, has been found to increase the 
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detection rate of prostate cancer significantly.[9] However, 
no study on the usefulness of extended biopsy protocol has 
been done in our environment or sub-region to the best of 
our knowledge. There is, therefore, a need to evaluate the 
biopsy protocols with different number of cores, with the 
aim of determining the optimal biopsy protocol for patients 
at risk of prostate cancer in our environment. The main aim 
of this study was to determine the significance of extended 
10-core biopsy protocol on cancer detection in different 
categories of patients being evaluated for prostate cancer.
Materials and Methods
This study was carried out prospectively amongst 125 men 
who were being investigated for cancer of the prostate 
between January and December 2010. Informed consent 
from the patients and approval from the ethical committee 
of Lagos University Teaching Hospital were obtained. 
They all had a DRE, PSA measurement, and prostate scan 
followed by prostate biopsy. Indications for prostate biopsy 
included presence of one or combination of elevated PSA 
and abnormal DRE, irrespective of findings on trans-
abdominal ultrasound of the prostate. All patients had an 
extended transrectal digitally guided prostate biopsy using a 
size 16 spring-loaded semi-automated Tru-Cut biopsy after 
rectal lubrication with 2% xylocaine hydrochloride jelly. All 
patients also had intravenous Pentazocin 30 mg, Diazepam 
5 mg, and Ciprofloxacin 200 mg stat before the procedure. 
“Sextant biopsies” were obtained from the apex, middle, and 
base of each lateral lobe para-sagittally. Additional four core 
biopsies, two cores from each lateral lobe, were obtained 
in all patients to make extended 10-core biopsies from the 
far lateral portion of the prostate by directing the needle 
laterally under digital guidance. These additional four cores 
were put together in a separate bottle and labeled as the 
“Lateral biopsies”. Samples were analyzed separately by the 
same pathologist to avoid inter-observer error. The results 
of biopsy histopathology were documented as malignant, 
benign, or prostatic intra-epithelial neoplasia (PIN). The 
overall histopathology from combination of the two biopsy 
protocols’ specimens termed “Extended biopsies” was 
reported as well as the results of Sextant biopsies separately.
A structured pro forma was used to obtain relevant patients’ 
information including the demographic data, examination 
findings, results of PSA, indication(s) for biopsy, and 
histopathology results. The data obtained from all patients 
on the pro forma were analyzed with Statistical Package 
for the Social Science (SPSS), version 16. The results were 
displayed in tables and charts. Cancer detection rates of 
sextant and extended biopsy protocols were determined 
and compared at different PSA ranges and different DRE 
findings. Level of significance of difference in cancer 
detection was determined using Pearson’s Chi square test 
with level of significance set at <0.05.
Results
A total of 125 patients were enrolled for the study. Ages 
of patients ranged from 47 to 95 years with a mean age of 
67.2 ± 10.5 years. Ninety-three (74.4%) were men above 
60 years of age. Men in their seventh decade of life 
accounted for 41.6% of the entire study population. 
[Table 1]
The PSA range was 0.6 to 149 with a mean of 23.4 ± 
18.46 ng/mL. Majority of study population, consisting of 
78 patients (62.4%), had elevated serum PSA of above 
10.0 ng/ mL. Thirty-six (28.8%) had borderline (gray zone) 
PSA of 4.1–10.0 ng/mL while 11 (8.8%) had a normal PSA 
level of less than 4 ng/mL. [Table 2]
Indications for prostate biopsy were elevated PSA alone in 
41 (32.8%) patients, abnormal DRE alone in 12 (9%), and 
combination of elevated PSA and abnormal DRE finding(s) 
in 72 (57.6%). A total of 84 (67.2%) patients had palpable 
abnormalities in the prostate while a total of 113 (90.4%) 
had elevated PSA.
Sixty-one (48.8%) of the 125 patients had malignant 
histology, 60 (48%) were benign, while 4 (3.2%) had PIN. 
All malignant biopsies were adenocarcinomas.
Amongst the 61 patients diagnosed to have cancer by 
the extended (combination) technique, only 52 of them 
were detected by the sextant technique of biopsy with 
an improvement of cancer detection in nine patients, 
amounting to an increase of 14.8%. This was found to be 
statistically significant with a P-value of 0.046. [Figure 1]
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Cancer detection rates of sextant and extended biopsy 
protocols were determined at different levels of PSA. 
There was statistically significant increase in detection rate 
of 33% by the extended protocol at PSA range of 4.1–10 
ng/mL with P-value of 0.04. Detection was improved 
in PSA range of 10.1–20.0 ng/mL by 20% but was not 
significant (0.067). There was no significant difference 
in detection rate at all levels of PSA above 10 ng/mL. 
(P>0.05) [Figure 2]
Amongst the 45 patients with normal DRE, sextant 
protocol detected cancers in 12 (26.7%) patients while 16 
(35.6%) were detected by the extended protocol with an 
improvement in detection rate of 25%. This is statistically 
significant with P-value of 0.047. Cancer detection rates 
amongst individuals with abnormal DRE were 40 (50%) and 
45 (56.3%) by sextant and extended protocols, respectively, 
with an improvement of 11.1%. This is not statistically 
significant. (P=0.186.)
Cancer detection by sextant and extended protocols in 
relation to the DRE findings amongst patients with gray-
zone PSA showed detection rates of 12.5% (2/16) and 
25% (4/16), respectively, with an improvement of 50% in 
patients with normal DRE findings. Detection rates were 
30% (6/20) and 40% (8/40), respectively, with an increase 
of 25% in those with abnormal DRE findings. Both were 
statistically significant with P-values of 0.037 and 0.049, 
respectively.
The range of Gleason score was 3–10 with a mean of 6.3 
amongst the 61 patients diagnosed to have cancer. In 
38 patients, the scores and the grades were exactly the 
same for cancers detected by both sextant and extended 
biopsies. The Gleason grades were different but with same 
score in 5 cases. Both grades and score differed in 6 cases 
with an average increase in the Gleason score of 0.8. Nine 
(14.8%) cases were detected by extended biopsies only. The 
average Gleason score for these additional cases was 6.4 
with no significant difference with others. Four (66.7%) of 
these six cases were in the gray zone with an average score 
of 6.37. There was no significant difference in the scores 
of additional cases detected by the extended biopsies in 
patients with PSA between 4 and 10 ng/mL and other PSA 
ranges as well.
Discussion
Prostate cancer is a global disease and its detection has greatly 
been facilitated by the discovery of PSA measurements.[10] 
The optimal biopsy protocol for patients has been a matter 
of debate with emphasis on biopsy protocol that maximizes 
cancer detection with minimal discomfort and an acceptable 
complication rate.
In this study, men above 60 years of age constituted about 
three-quarters of the study population, signifying that 
prostatic diseases are common among the elderly.[1,2] The 
mean age of 67.2 years in this study agrees with findings of 
other researchers in the literature.[11-13]
Elevated total PSA level was the commonest indication for 
biopsy. Forty-one (33%) patients had elevated PSA only 
while 72 (58%) had elevated PSA in addition to abnormal 
DRE findings. Prior to the PSA era, nearly 70% of men 
diagnosed with prostate cancer already had extra-prostatic 
or metastatic disease, as an abnormality in the prostate had 
to be palpably evident before a biopsy was performed.[14] 
With the advent of PSA evaluation, majority of patients are 
diagnosed at an early stage, including asymptomatic patients 
who had biopsy after PSA screening in the advanced 
countries. This is, however, not entirely true in sub-Saharan 
Africa where the benefit of PSA as a screening tool has not 
been fully used. This is reflected in this study as majority, 84 
(67.2%) patients, had palpable abnormalities in the prostate 
at presentation while only 41 (32.8%) had biopsy on account 
of PSA alone. However, this is in contrast to a study carried 
out by Awojobi et al.[15] in Ibadan more than two decades ago 
where abnormal DRE was the sole indication for biopsy in 
more than 65% of patients. This implies that development 
of PSA measurement has significantly changed the way 
men with suspected prostate cancer are evaluated in our 
environment and has also enabled diagnosis of prostate 
cancer in men with early-stage disease without clinical 
evidence of malignancy.
Figure 1: Comparison of overall detection by biopsy protocols
Figure 2: Comparison of cancer detection by techniques at 
different PSA ranges
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The overall cancer detection rate was 48.8% in this study. 
This is higher than the findings in most other studies where 
detection rates vary from 18.6 to 42.6%. This may not be 
unconnected with late presentation in our environment. 
[12,16] This fact is supported by the fact that 78 (62.4%) 
patients in this study had PSA of > 10ng/mL.
Among the 61 patients that were positive for malignancy 
by extended biopsy protocol, sextant protocol detected 
cancers in 52 patients. Considering cancer detection rate of 
both biopsy protocols at different PSA levels, we observed 
that there was a statistically significant improvement in 
detection rate by the extended over the sextant protocol 
in patients with PSA range of 4.1–10 ng/mL. In this subset, 
the sextant technique detected eight (8) cancers only while 
the extended technique detected a total number of twelve 
(12) cases. This is a 33.3% increase in prostate cancer 
detection rate by the addition of the four lateral biopsies in 
this category of patients and was found to be statistically 
significant (P=0.04). This may be due to small size and 
volume of the disease in early stages as opposed to large size 
and volume in advanced malignancies, which can be readily 
detected by sextant or targeted biopsies. In addition, the 
peripheral zone, which is usually left unsampled in sextant 
para-sagittal biopsies, is believed to be the site of origin for 
most early cancers before extension to other aspects of the 
prostate.[17,18] However, for PSA ranges above 10 ng/mL, 
cancer detection rates were not affected significantly by 
increased number of cores. Though detection was improved 
by extended protocol in patients with PSA between 10.1 and 
20.0 ng/mL, the improvement was found to be statistically 
insignificant. (P=0.067) Based on the mean PSA value 
of 23.4 ng/mL in this study, it could be assumed that most 
of the patients were likely to have advanced disease with 
greater tumor size/volume. This is probably responsible for 
the similar detection rates by sextant and extended biopsy 
protocols in all categories of patients with elevated PSA level 
more than 10.0 ng/mL. Djavan et al.[19] in their study also 
documented that sextant biopsy is sub-optimal in patients 
with gray-zone PSA between 4 and 10ng/mL and suggested 
extended biopsy protocol for these patients. This finding also 
suggests that sextant protocol would still be appropriate in 
advanced cases.
It is a well-known fact that the ability of serum PSA to 
distinguish between benign and malignant conditions 
is particularly poor in the intermediate range of 4.1 and 
10 ng/ mL.[10] Thus, additional PSA parameters like PSA 
velocity, PSA density, and PSA adjusted for transitional 
zone have been suggested to improve the sensitivity and 
specificity of PSA. This study has demonstrated that 
performing an extended prostate biopsy is another important 
way of improving cancer detection in these patients.[8]
There was significant improvement in the diagnostic yield 
of 25% by the extended 10-core biopsy technique over the 
conventional sextant technique with a P-value of 0.048 in 
men with normal DRE findings, irrespective of their PSA 
values. This was not so in patients with clinically palpable 
abnormalities where detection was increased by 11.1%. This 
may be due to the fact that clinical evidence of malignancy 
on DRE often connotes advancement with possible 
increased tumor volume in contrast to early cancers without 
palpable abnormality because of small tumor size. This shows 
that DRE finding is another important factor in determining 
the best biopsy technique for patients. An extended 10-core 
technique is, therefore, highly recommended in patients who 
have normal DRE, irrespective of their serum PSA level.
In this study, there was a significant total improvement of 
33% in diagnostic yield in patients with gray-zone PSA, with 
or without abnormality on DRE. However, the improvement 
is much higher in patients with both gray-zone PSA and a 
normal DRE, with an increase in cancer detection of 50% as 
opposed to 25% increase in those with gray-zone PSA and 
palpable abnormality. Therefore, one can safely conclude 
that a PSA of 4.1–10.0 ng/mL in the presence of a normal 
DRE is a very strong indication for an extended 10-core 
prostatic needle biopsy.
The range of Gleason score was 3–10 with a mean of 6.3. 
This implies that most of the patients had moderate grade 
histology. Though there were few disparities in the Gleason 
scores and grades, cancers detected by both sextant and 
extended protocols were similar in patients in all PSA ranges. 
Cancers detected by extended protocol only also have 
similar characteristics in patients with PSA between 4 and 
10 ng/ mL and in other PSA ranges. However, the significance 
of this cannot be stated with certainty and further studies 
with higher number of study populations will be required. 
Also, the result of this study does not establish any direct 
relationship between PSA levels and Gleason scores.
Conclusion
With an overall improvement in detection rate of 33% in 
patients with gray-zone PSA irrespective of the DRE findings 
and a 50% improvement in patients with gray-zone PSA 
and normal DRE findings, this suggests that an extended 
10-core biopsy technique should be the appropriate or 
optimal biopsy protocol in patients with gray-zone PSA. This 
biopsy technique is much more important in patients with 
a gray-zone PSA and normal DRE findings. The use of the 
traditional sextant protocol in patients with high PSA and 
abnormal DRE findings is still recommended.
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